Understanding genetic and developmental factors in early-onset epilepsy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the genotype, phenotype, and disease progression of children diagnosed with developmental epileptic encephalopathy who are under 2 years of age. It focuses on identifying genetic causes of epilepsy and their correlation with developmental outcomes, including intellectual disabilities and autism spectrum disorders. The study will follow participants for two years to assess how these factors influence the progression of their condition. The research is particularly significant as it addresses a gap in knowledge regarding early-onset epilepsy in Vietnam.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Diagnosed with Early infantile developmental and epileptic encephalopathy or Epilepsy of infancy with migrating focal seizures or infantile spasms syndrome or severe myoclonic epilepsy of infancy or Epilepsy with myoclonic-atonic seizures
2. Diagnosed with drug-resistant epilepsy according to ILAE 2010 criteria
3. Age at the start of participating in the study ranged from 0 to 23 months old
4. Relatives agree to participate in the research
5. There is no medical history of any diagnosis of hypoxic encephalopathy or inflammatory encephalopathy or traumatic encephalopathy or cerebral infarction or cerebral hemorrhage.

Exclusion Criteria:

Patients were removed from the study when they were lost to follow-up at 6 months

\-

Where it's running

• Children hospital number 2
  Ho Chi Minh City, Vietnam Recruiting
• University of Medicine and Pharmacy at Ho Chi Minh city
  Ho Chi Minh City, Vietnam Recruiting

Study contacts

• Study coordinator: Thuy-Minh-Thu Thuy Minh NGUYEN, MD
• Email: dr.thu.nguyen.neurology@gmail.com
• Phone: +84983966371

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-personalized Medilepsy app to help teens and young adults with epilepsy manage medicines and transition to adult care

  This trial tests whether an AI-personalized Medilepsy app helps underserved adolescents and young adults with epilepsy (ages 14–24) take their anti-seizure medicines and prepare for adult care better than the standard app.

  Recruiting at 2 sites University of Central Florida · Orlando, Florida and 1 other locations · NCT07445074

• Project PENGUIN: Profiling phenotypic, epigenetic, and neurogenetic traits in rare neurodevelopmental disorders

  This project will try to collect clinical data, genetic and epigenetic samples, imaging, and skin-derived cell models from people with rare neurogenetic disorders like SYT1/BAGOS to help track disease and support future treatments.

  Recruiting University of Missouri-Columbia · Columbia, Missouri · NCT07329257

• Long-term RAP-219 treatment for adults with focal onset seizures

  This trial will try RAP-219, an investigational anti-seizure medication, in adults with refractory focal seizures to see if it is safe long-term and helps reduce seizures.

  Recruiting at 7 sites Phase 2 Rapport Therapeutics Inc. · Boise, Idaho and 6 other locations · NCT07219407

• Vascular risk screening and management after late-onset seizures

  This project will test whether screening and treating blood pressure, cholesterol, BMI and other vascular risks in people who have their first unprovoked seizure after age 50 can lower their future risk of stroke and heart disease.

  Recruiting at 3 sites Sahlgrenska University Hospital · Borås and 2 other locations · NCT07116330

• Detecting thalamus seizures using a Percept deep brain stimulator

  This project will test whether the Medtronic Percept DBS device can reliably detect seizures from the thalamus in adults with drug-resistant epilepsy.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT06700356

• Optimizing brain stimulation for epilepsy treatment

  This study is testing whether low or high frequency brain stimulation can help people with epilepsy control their seizures better.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT06617845

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.